Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.55 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.55 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.55 |
| ▸ | GHSR | Q92847 | 2/20 | 0.55 |
| ▸ | ECE1 | P42892 | 6/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30052005 | 0.93 | CTSC (0.69) | CTSCMEN1KMT2AACEERAP2 | |
| SCHEMBL31468798 | 0.92 | GHSR (0.60) | ACEERAP2ERAP1LNPEPGHSR | |
| SCHEMBL29924977 | 0.92 | GHSR (0.60) | ACEERAP2ERAP1LNPEPGHSR | |
| SCHEMBL29925186 | 0.92 | GHSR (0.60) | ACEERAP2ERAP1LNPEPGHSR | |
| SCHEMBL30051511 | 0.91 | CTSC (0.64) | CTSCMEN1KMT2AACEERAP2 | |
| SCHEMBL1939431 | 0.91 | ACE (0.63) | MEN1KMT2AACEERAP2ERAP1 | |
| SCHEMBL30659503 | 0.91 | ACE (0.63) | MEN1KMT2AACEERAP2ERAP1 | |
| SCHEMBL1939435 | 0.91 | ACE (0.63) | MEN1KMT2AACEERAP2ERAP1 | |
| SCHEMBL30051830 | 0.90 | CTSC (0.71) | CTSCMEN1KMT2AACEERAP2 | |
| SCHEMBL13154782 | 0.90 | CTSC (0.73) | CTSCMEN1KMT2AACEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109962-A1 | METHOD FOR THE PRODUCTION OF AN ENZYMATIC COMPOSITION COMPRISING A RECOMBINANT ENDOPEPTIDASE | NEMYSIS LIMITED (IE) | 2026-04-23 | — | — | US | disclosed |
| US-20220364069-A1 | METHOD FOR THE PRODUCTION OF AN ENZYMATIC COMPOSITION COMPRISING A RECOMBINANT ENDOPEPTIDASE | NEMYSIS LIMITED (IE) | 2022-11-17 | — | — | US | disclosed |
| EP-4004199-A1 | METHOD FOR THE PRODUCTION OF AN ENZYMATIC COMPOSITION COMPRISING A RECOMBINANT ENDOPEPTIDASE | Nemysis Limited (IE) | 2022-06-01 | — | — | EP | disclosed |
| CN-114174519-A | Method for producing enzyme composition comprising recombinant endopeptidase | 内米西斯有限公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109962-A1 | METHOD FOR THE PRODUCTION OF AN ENZYMATIC COMPOSITION COMPRISING A RECOMBINANT ENDOPEPTIDASE | CMA1, RNGTT, ENGASE | CTSC 46/4885MEN1 1907/4885KMT2A 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.